Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fisher, R. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fisher, R. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:S29-S33, 2000
© 2000 European Society for Medical Oncology

Symposium Articles

Diffuse large-cell lymphoma

R. I. Fisher, Coleman Professor of Oncology, Director

Cardinal Bernardin Cancer Center, Lymphoma Committee, Southwest Oncology Group, Loyola University Chicago Maywood, IL, USA

Correspondence to: R. I. Fisher, MD Director, Cardinal Bernardin Cancer Center Loyola University Medical Center 2160 S. First Ave. Maywood, IL 60153 USA

Background: New treatments are desperately needed to improve the results obtained using CHOP chemotherapy for patients with diffuse large cell lymphoma. In order to develop successful new strategies we need to understand why prior promising therapies have failed and to develop new testable hypotheses based on our current knowledge.

Patients and methods: The International Non-Hodgkin's Lymphoma Prognostic Factors Index has provided us with a methodology to compare the expected prognosis of patients on different clinical trials. Many prior, apparent improvements in treatment outcome can now be attributed to the inclusion of patients with better prognoses.

Results: Current areas of investigation include: 1) the identification of new active drugs for the treatment of lymphoma, 2) the use of colony stimulating factors to allow dose escalation of the active myelotoxic drugs. 3) the use of strategies which may overcome the problem of resistance to chemotherapy, 4) the combination of monoclonal antibodies with combination chemotherapy and 5) ablative chemotherapy with autologous stem-cell support.

Conclusions: Based on all of the available data, the North American Lymphoma Intergroup has developed the hypothesis that high-intermediate and high risk patients with aggressive lymphoma who receive full course standard induction therapy will benefit form the addition of high dose therapy and has antedated a clinical trial testing that hypothesis.

autologous transplantation, CHOP, diffuse large B-cell lymphoma, IPI, NHL


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.